7-hydroxy-3-(3-hydroxy-4-methoxyphenyl)-6-methoxy-4H-1-benzopyran-4-one | 53948-00-8

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 异黄酮类化合物
• 英文名称: 7-hydroxy-3-(3-hydroxy-4-methoxyphenyl)-6-methoxy-4H-1-benzopyran-4-one
• 英文别名: 3′,7-dihydroxyl-4′,6-dimethoxylisoflavone；3',7-dihydroxy-4',6-dimethoxyisoflavone；7,3'-dihydroxy-6,4'-dimethoxyisoflavone；7,3'-dihydroxy-6.4'-dimethoxyisoflavone；odoratin；7-hydroxy-3-(3-hydroxy-4-methoxy-phenyl)-6-methoxy-chromen-4-one；7-hydroxy-3-(3-hydroxy-4-methoxyphenyl)-6-methoxychromen-4-one
• CAS: 53948-00-8
• 化学式: C₁₇H₁₄O₆
• 分子量: 314.295
• InChiKey: BYNYZQQDQIQLSO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  85.2
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  7-(β-D-glucopyranosyloxy)-6-methoxy-3-(3-hydroxy-4-methoxyphenyl)-4H-1-benzopyran-4-one 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 反应 0.5h， 以49 mg的产率得到7-hydroxy-3-(3-hydroxy-4-methoxyphenyl)-6-methoxy-4H-1-benzopyran-4-one
  参考文献：
  名称：

  Odoratin 7-O-β-D-glucopyranoside from Bowdichia virgilioides

  摘要：

  An isoflavonoid glucoside, odoratin 7-O-beta-D-glucopyranoside, was isolated from the roots of Bowdichia virgilioides and its structure was established by spectroscopic and chemical methods. In vitro tests showed that this compound inhibited both T-lymphocyte and B-lymphocyte proliferation. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0031-9422(99)00459-8

文献信息

• USE OF PTEROCARPANS AS ACTIVE ANTI-CELLULITE INGREDIENTS
  申请人：Meyer Imke

  公开号：US20110034486A1

  公开（公告）日：2011-02-10

  The invention relates to a cosmetic, dermatological or pharmaceutical preparation, containing one, two or more compounds of formula (I) and/or a pharmaceutically acceptable salt of a compound of this type, (i) for use in a method for preventing, treating or reducing cellulite, and/or (ii) in an adequate quantity to reduce the lipid quantity contained in subcutaneous fat tissue, and/or to inhibit the differentiation of preadipocytes, and/or to inhibit the lipogenesis in adipocytes, wherein the radicals R1 to R8, independently of one another, signify hydrogen, hydroxy or C1-C4-alkoxy, and/or two adjacent radicals together form a methylenedioxy group.

  该发明涉及一种化妆品、皮肤学或药用制剂，包含一个、两个或更多的式(I)化合物和/或该类型化合物的药用盐，(i)用于预防、治疗或减少脂肪团，和/或(ii)以适量减少皮下脂肪组织中所含的脂质量，和/或抑制脂肪前体细胞的分化，和/或抑制脂肪细胞中的脂肪合成，在该式中，基团R1至R8，彼此独立地表示氢、羟基或C1-C4-烷氧基，和/或两个相邻的基团一起形成亚甲二氧基基团。
• Use of a plant extract or plant juice
  申请人：Melbrosin International Produktions und Vertriebs GmbH & Co KG

  公开号：EP1925311A1

  公开（公告）日：2008-05-28

  Use of a plant extract or plant juice for the production of a pharmaceutical or nutritional preparation for the treatment of metabolic syndrome, wherein the plant extract or juice is from thyme, oregano, glove, nutmeg, red clover, bay leaves or red onion, as well as chemical compounds usually obtainable from plants for this use.

  将植物提取物或植物汁用于生产治疗代谢综合征的药物或营养制剂，其中植物提取物或植物汁来自百里香、牛至、手套、肉豆蔻、红三叶草、月桂叶或红洋葱，以及通常可从植物中获得的用于此用途的化合物。
• Verwendung von Pterocarpanen als Anti-Cellulite-Wirkstoffe
  申请人：Symrise AG

  公开号：EP2295031A2

  公开（公告）日：2011-03-16

  Beschrieben wird eine kosmetische, dermatologische oder pharmazeutische Zubereitung, enthaltend eine, zwei oder mehr Verbindungen der Formel (I) und/oder ein pharmazeutisch akzeptables Salz einer solchen Verbindung, (i) zur Anwendung in einem Verfahren zur Vorbeugung, Behandlung oder Verringerung von Cellulite, und/oder (ii) in einer ausreichenden Menge - zum Reduzieren der in subkutanem Fettgewebe enthaltenen Lipidmenge, und/oder - zum Hemmen der Differenzierung von Preadipozyten, und/oder - zum Hemmen der Lipogenese in Adipozyten, wobei die Reste R1 bis R8, unabhängig voneinander, Wasserstoff, Hydroxy oder C1-C4-Alkoxy bedeuten, und/oder zwei benachbarte Reste gemeinsam eine Methylendioxygruppe bilden. Beschrieben werden auch entsprechende Verfahren sowie Verwendungen.

  本文描述了一种含有一种、两种或多种式（I）化合物和/或此类化合物的药学上可接受的盐的化妆品、皮肤病或药物制剂、 (i) 用于预防、治疗或减少脂肪团的方法，和/或 (ii) 其用量足以 - 减少皮下脂肪组织中的脂质含量，和/或 - 抑制前脂肪细胞的分化，和/或 - 抑制脂肪细胞的脂肪生成、 其中 R1 至 R8 自由基分别为氢、羟基或 C1-C4- 烷氧基，和/或两个相邻自由基共同形成亚甲二氧基。还描述了相应的方法和用途。
• Method of decreasing liquiritigenin-derived isoflavones relative to total isoflavones in plants and plants producing reduced ratio of liquiritigenin-derived isoflavones relative to total isoflavones
  申请人：——

  公开号：US20040128714A1

  公开（公告）日：2004-07-01

  This invention pertains to methods for decreasing the ratio of liquiritigenin-derived isoflavones relative to total isoflavone levels in isoflavonoid-producing plants and plant parts by transforming plants with a recombinant DNA construct comprising a nucleic acid sequence of at least 200 nucleotides and having at least 75% sequence identity to a polynucleotide encoding a chalcone reductase. More preferably, this invention pertains to methods for decreasing the ratios of daidzein and glycitein and their conjugates relative to total isoflavone levels in soybean plants and soybean plant parts by transforming plants with a recombinant DNA construct comprising a nucleic acid sequence of at least 200 nucleotides and having at least 75% sequence identity to a polynucleotide encoding a chalcone reductase.

  本发明涉及通过用重组 DNA 构建体转化植物来降低产生异黄酮的植物和植物部位中来源于利吉霉素的异黄酮相对于总异黄酮水平的比率的方法，该 DNA 构建体包含至少 200 个核苷酸的核酸序列，并且与编码查耳酮还原酶的多核苷酸具有至少 75% 的序列同一性。更优选地，本发明涉及通过用重组 DNA 构建体转化植物来降低大豆植物和大豆植物部位中的大豆异黄酮和甘草甜素及其共轭物相对于总异黄酮水平的比率的方法，该 DNA 构建体包含至少 200 个核苷酸的核酸序列，且与编码查尔酮还原酶的多核苷酸具有至少 75% 的序列同一性。
• Compositions and method for treatment of steroid/nuclear receptor-mediated diseases
  申请人：Yong Eu Leong

  公开号：US20050118290A1

  公开（公告）日：2005-06-02

  Compositions and method for treatment of steroid/nuclear receptor-mediated diseases. The present invention relates to non-aqueous extracts of Astragalus Membranaceus (HQ) and to compositions thereof. Also provided is a method for the treatment of PPAR-mediated physiological conditions comprising administering to a subject an effective amount of at least one of the above mentioned extracts and also a method for augmenting or synergising the activity of ligands of steroid/nuclear receptors comprising administering to a subject an effective amount of at least one of: an extract of Astragalus Membranaceus (HQ) or a flavonoid compound; in the presence of at least one ligand of steroid/nuclear receptors.

  治疗类固醇/核受体介导的疾病的组合物和方法。本发明涉及以下非水提取物 黄芪 (HQ）的非水提取物及其组合物。本发明还提供了一种治疗 PPAR 介导的生理状况的方法，该方法包括向受试者施用有效量的至少一种上述提取物，以及一种增强或协同类固醇/核受体配体活性的方法，该方法包括向受试者施用有效量的至少一种下列提取物：黄芪（HQ）提取物、黄芪提取物、黄芪提取物、黄芪提取物、黄芪提取物、黄芪提取物、黄芪提取物、黄芪提取物、黄芪提取物、黄芪提取物、黄芪提取物、黄芪提取物、黄芪提取物。 黄芪提取物 (HQ) 的提取物或黄酮类化合物；在至少一种类固醇/核受体配体存在的情况下。